To summarize, NF-κB activity is already upregulated at the adenoma stage and is activated further along with ITF2 suppression at the carcinoma stage, which further supports our hypothesis that ITF2 loss renders tumors more malignant by increasing NF-κB activation. The gene discussed is NFKB1; the disease is adenoma.